If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.00
Bid: 2.00
Ask: 2.05
Change: -0.075 (-3.61%)
Spread: 0.05 (2.50%)
Open: 2.05
High: 2.09
Low: 2.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: ImmuPharma waits on FDA; IDE Group waits on audit

Wed, 31st Aug 2022 21:41

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

ImmuPharma PLC - specialist drug discovery and development company - Says US partner for Lupuzor, Avion Pharmaceuticals, yet to meet US Food & Drug Administration. "The company is in close contact with Avion and have been advised that the FDA is experiencing general delays in meeting response dates and that this is not specific to Avion and the Type C meeting for Lupuzor. The company will notify the market as soon as practicable once a response from the FDA has been received," it adds.

----------

IDE Group Holdings PLC - Edinburgh-based network, cloud and IT managed services - Auditors request further time to complete work on firm's 2021 results. "The delay in publication relates to the cumulative impact of Covid, including related staff absences from Covid and the resulting knock on impact on the audit process, as previously announced," it says. Expects release before end of September. Had already delayed results, and was expecting them towards the end of July. Previously notes results are expected to show trading Ebitda of GBP3.0 million, but this could "potentially increase" as a result of various potential non-trading audit adjustments.

----------

Galantas Gold Corp - Northern Ireland-focused gold producer - Closes CAD6.9 million, about USD5.3 million, private placement, after upping fundraising with previously hoping to raise CAD4 million. Sells 14.8 million units at CAD0.45 each and further 506,667 units at same price. Each unit holds one share and one-half share warrant. Each warrant can be exchanged for one share, at CAD0.55, until February 28. "The company intends to use the net proceeds of the upsized offering for exploration and development at the Joshua Target as well as for working capital and general corporate purposes," it has previously said.

----------

Castillo Copper Ltd - Perth, Australia-based exploration company focused on copper across Australia and Zambia - Appoints two contractors for the upcoming drilling campaign at the Broken Hill Alliance project's East zone. Drilling expected to begin in fourth quarter, subject to regulatory approval from Australia's NSW resources regulator. Managing Director Dennis Jensen "delighted" with appointment of AllState and FieldCrew.

----------

Phoenix Global Resources PLC - London-based upstream oil and gas company focused on Argentina - Says shareholder holding 2% of issued capital sends letter to firm about "certain claims alleged against the company and other parties." Adds: "The board is taking legal advice in relation to the letter and believes the claims that it alleges to be without merit." Has previously proposed delisting from AIM and the Buenos Aires Stock Exchange, providing a "cash exit opportunity for shareholders" in the process. Major shareholder Mercuria Energy Group Ltd, which holds an 84% stake, proposes purchasing shares at 7.5p each under the exit opportunity, a 25% premium to its closing price on June 25, the day before it discussed a potential delisting with Mercuria. Will hold general meeting on September 1 to gain at least 75% shareholder approval for the delisting and the scheme.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
20 Dec 2021 11:41

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Read more
20 Dec 2021 11:22

ImmuPharma raises £3.55m to fund research pipeline

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced subscriptions and a placing to raise £3.55m on Monday, to fund its research and development pipeline as well as general working capital.

Read more
20 Dec 2021 10:15

ImmuPharma surges after raise at "significant premium" to share price

ImmuPharma surges after raise at "significant premium" to share price

Read more
29 Nov 2021 20:45

TRADING UPDATES: ImmuPharma teams with Imperial; Webis results delayed

TRADING UPDATES: ImmuPharma teams with Imperial; Webis results delayed

Read more
29 Nov 2021 13:32

ImmuPharma signs two-year collaboration deal with Imperial College

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Monday that it has signed a two-year collaboration agreement with Imperial College London.

Read more
18 Nov 2021 20:53

TRADING UPDATES: Abingdon Health swings to loss; MetalNRG in dispute

TRADING UPDATES: Abingdon Health swings to loss; MetalNRG in dispute

Read more
18 Nov 2021 15:16

ImmuPharma reports 'significant' progress since restructure

(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported "significant" positive progress on Thursday, following major changes to its board and a restructuring of senior management in August.

Read more
1 Oct 2021 11:47

IN BRIEF: Immupharma leaves Euronext Growth Brussels market

IN BRIEF: Immupharma leaves Euronext Growth Brussels market

Read more
29 Sep 2021 20:31

IN BRIEF: ImmuPharma to make cost savings as it simplifies structure

IN BRIEF: ImmuPharma to make cost savings as it simplifies structure

Read more
29 Sep 2021 13:22

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

Read more
24 Aug 2021 15:08

DIRECTOR DEALINGS: Gamesys, Capital and ActiveOps execs sell shares

DIRECTOR DEALINGS: Gamesys, Capital and ActiveOps execs sell shares

Read more
12 Aug 2021 14:17

IN BRIEF: Immupharma gets US FDA approval for Lupuzor pre-trial study

IN BRIEF: Immupharma gets US FDA approval for Lupuzor pre-trial study

Read more
12 Aug 2021 13:02

FDA gives ImmuPharma go-ahead for pharmacokinetic study

(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Thursday that the United States Food and Drug Administration (FDA) has approved the start of the pharmacokinetic study as part of its new, "optimised" international phase 3 trial of 'Lupuzor'.

Read more
30 Jul 2021 15:34

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

Read more
16 Jul 2021 11:24

IN BRIEF: ImmuPharma appoints COO Tim Franklin to board of directors

IN BRIEF: ImmuPharma appoints COO Tim Franklin to board of directors

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.